Cardiol Therapeutics (CRDL) Operating Income (2020 - 2026)

Cardiol Therapeutics has reported Operating Income for 6 years, with the latest figure at -$7.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 20.49% year-over-year to -$7.1 million; the trailing twelve-month figure through Mar 2026 stood at -$25.9 million (up 10.56% YoY), and the FY2025 full-year result was -$24.6 million, up 14.65% from the prior year.
• Operating Income for Q1 2026 stood at -$7.1 million, down from -$5.9 million in the prior quarter.
• The five-year high for Operating Income was -$5.9 million in Q1 2025, with the low at -$10.1 million in Q3 2022.
• Historically, Operating Income has averaged -$7.3 million across 4 years, with a median of -$7.1 million in 2026.
• The largest YoY upside for Operating Income was 35.52% in 2022 against a maximum downside of 38.57% in 2022.
• Cardiol Therapeutics' Operating Income stood at -$6.7 million in 2022, then gained by 6.9% to -$6.2 million in 2024, then grew by 5.83% to -$5.9 million in 2025, then fell by 20.49% to -$7.1 million in 2026.
• The last three Operating Income figures came in at -$7.1 million (Q1 2026), -$5.9 million (Q1 2025), and -$6.2 million (Q1 2024), per Business Quant data.